The Emerging Role of Arid5a in Cancer: A New Target for Tumors

Overview

Journal Genes Dis

Date 2023 Jul 3

PMID 37396543

Authors

Kishan Kumar Nyati

Tadamitsu Kishimoto

Affiliations

Soon will be listed here.

Abstract

AT-rich interactive domain 5a (Arid5a) is a member of the arid family of proteins, which contain a helix-turn-helix domain and an ability to bind to nucleic acids. Current evidence suggests that Arid5a performs dual functions as a transcription factor and an RNA-binding protein in immune, nonimmune, and/ or tumor cells depending on its cellular localization. The contribution of Arid5a to the development of inflammation, autoimmunity, and obesity through its transcriptional and posttranscriptional regulatory functions has broadly been reviewed. Recent studies have indeed revealed an association of Arid5a with cancers, including breast, pancreatic, colorectal, and lung cancers and glioma. Notably, Arid5a affects various aspects of cellular homeostasis, including invasion, metastasis, epithelial-to-mesenchymal transition, immune evasion, adipogenesis and M1-like tumor-associated macrophage (TAM)-to-M2-like TAM transition. This review aims to summarize current knowledge of Arid5a from a cancer perspective and highlights recent advances in Arid5a-related cancer research. This review may improve the understanding of Arid5a-mediated molecular mechanisms and their relevance to cancers.

Citing Articles

Single-Cell Sequencing and Transcriptome Analysis Explored Changes in Midnolin-Related Immune Microenvironment and Constructed Combined Prognostic Model for Pancreatic Cancer.

Guan X, Xu L, Liu J, Fei H, Wang C J Inflamm Res. 2025; 18:2975-2990.

PMID: 40026303 PMC: 11872096. DOI: 10.2147/JIR.S503326.

Interleukin-6 Modulation in Ovarian Cancer Necessitates a Targeted Strategy: From the Approved to Emerging Therapies.

Amer H, Kampan N, Itsiopoulos C, Flanagan K, Scott C, Kartikasari A Cancers (Basel). 2025; 16(24.

PMID: 39766086 PMC: 11674514. DOI: 10.3390/cancers16244187.

Gene regulatory network topology governs resistance and treatment escape in glioma stem-like cells.

Park J, Hothi P, de Lomana A, Pan M, Calder R, Turkarslan S Sci Adv. 2024; 10(23):eadj7706.

PMID: 38848360 PMC: 11160475. DOI: 10.1126/sciadv.adj7706.

Non-apoptotic regulatory cell death scoring system to predict the clinical outcome and drug choices in breast cancer.

Zhou Q, Gao X, Xu H, Lu X Heliyon. 2024; 10(10):e31342.

PMID: 38813233 PMC: 11133894. DOI: 10.1016/j.heliyon.2024.e31342.

References

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Yuan Y, Whitson R, Liu Q, Itakura K, Chen Y . A novel DNA-binding motif shares structural homology to DNA replication and repair nucleases and polymerases. Nat Struct Biol. 1998; 5(11):959-64. DOI: 10.1038/2934. View

van Baren N, Van den Eynde B . Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan. Cancer Immunol Res. 2015; 3(9):978-85. DOI: 10.1158/2326-6066.CIR-15-0095. View

Wilsker D, Patsialou A, Dallas P, Moran E . ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 2002; 13(3):95-106. View

Van den Eynde B . Arid5a: A Missing Link between EMT and Tumoral Immune Resistance. Cancer Immunol Res. 2021; 9(8):854. DOI: 10.1158/2326-6066.CIR-21-0432. View

Kortschak R, Tucker P, Saint R . ARID proteins come in from the desert. Trends Biochem Sci. 2000; 25(6):294-9. DOI: 10.1016/s0968-0004(00)01597-8. View

Seidel J, Otsuka A, Kabashima K . Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol. 2018; 8:86. PMC: 5883082. DOI: 10.3389/fonc.2018.00086. View

Jewer M, Findlay S, Postovit L . Post-transcriptional regulation in cancer progression : Microenvironmental control of alternative splicing and translation. J Cell Commun Signal. 2012; 6(4):233-48. PMC: 3497899. DOI: 10.1007/s12079-012-0179-x. View

Huang T, Oka T, Asai T, Okada T, Merrills B, Gertson P . Repression by a differentiation-specific factor of the human cytomegalovirus enhancer. Nucleic Acids Res. 1996; 24(9):1695-701. PMC: 145859. DOI: 10.1093/nar/24.9.1695. View

10.

Di C, Mladkova N, Lin J, Fee B, Rivas M, Chunsheng K . AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival. Int J Oncol. 2017; 52(1):47-54. PMC: 5743336. DOI: 10.3892/ijo.2017.4184. View

11.

Georgescu S, Li J, Lu Q, Karas R, Brown M, Mendelsohn M . Modulator recognition factor 1, an AT-rich interaction domain family member, is a novel corepressor for estrogen receptor alpha. Mol Endocrinol. 2005; 19(10):2491-501. DOI: 10.1210/me.2004-0311. View

12.

Nyati K, Masuda K, Zaman M, Dubey P, Millrine D, Chalise J . TLR4-induced NF-κB and MAPK signaling regulate the IL-6 mRNA stabilizing protein Arid5a. Nucleic Acids Res. 2017; 45(5):2687-2703. PMC: 5389518. DOI: 10.1093/nar/gkx064. View

13.

Wang H, Wang X, Xu L, Zhang J, Cao H . Prognostic significance of age related genes in patients with lower grade glioma. J Cancer. 2020; 11(13):3986-3999. PMC: 7171497. DOI: 10.7150/jca.41123. View

14.

Mihara M, Moriya Y, Kishimoto T, Ohsugi Y . Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. Br J Rheumatol. 1995; 34(4):321-5. DOI: 10.1093/rheumatology/34.4.321. View

15.

Nyati K, Agarwal R, Sharma P, Kishimoto T . Arid5a Regulation and the Roles of Arid5a in the Inflammatory Response and Disease. Front Immunol. 2019; 10:2790. PMC: 6906145. DOI: 10.3389/fimmu.2019.02790. View

16.

Nyati K, Zaman M, Sharma P, Kishimoto T . Arid5a, an RNA-Binding Protein in Immune Regulation: RNA Stability, Inflammation, and Autoimmunity. Trends Immunol. 2020; 41(3):255-268. DOI: 10.1016/j.it.2020.01.004. View

17.

Amano K, Hata K, Muramatsu S, Wakabayashi M, Takigawa Y, Ono K . Arid5a cooperates with Sox9 to stimulate chondrocyte-specific transcription. Mol Biol Cell. 2011; 22(8):1300-11. PMC: 3078073. DOI: 10.1091/mbc.E10-07-0566. View

18.

Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister S . Glioma. Nat Rev Dis Primers. 2016; 1:15017. DOI: 10.1038/nrdp.2015.17. View

19.

Iwahara J, Clubb R . Solution structure of the DNA binding domain from Dead ringer, a sequence-specific AT-rich interaction domain (ARID). EMBO J. 1999; 18(21):6084-94. PMC: 1171673. DOI: 10.1093/emboj/18.21.6084. View

20.

Liang T, Wang X, Wang F, Feng E, You G . Galectin-9: A Predictive Biomarker Negatively Regulating Immune Response in Glioma Patients. World Neurosurg. 2019; 132:e455-e462. DOI: 10.1016/j.wneu.2019.08.117. View